• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Revised CDC Guidelines for HIV Testing Set to Benefit the HIV Diagnostics Market in the US

Posted on: Friday, 4 May 2007, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c55898) has announced the addition of Decisions Resources new report: Updated CDC HIV Testing Guidelines to Shape Evolving Diagnostics Market to their offering.

HIV/AIDS stands out as a highly lucrative and expanding market for diagnostics companies because of the close integration of diagnostics in initial diagnosis and subsequent day-to-day disease management. With the newly released CDC screening recommendations advocating increased testing for the infection, diagnostics will play an increasingly critical role in HIV disease management.

Get the Answers You Need to Shape Your Strategy

- The revised CDC guidelines for HIV testing are set to dramatically benefit the HIV diagnostics market in the United States. Which sectors of the diagnostics market will benefit most? What will be the long-term impact of the CDC recommendations?

- The new recommendations have changed HIV testing from an "opt-in" diagnostic to an "opt-out" test that is a routine part of medical practice. How will this new process affect the diagnosis rates for HIV? Will it dramatically increase treatment rates?

- HIV diagnosis is currently a multistep process that involves time-consuming confirmatory tests. In its new recommendations, the CDC advocates the use of rapid testing. How will the CDC recommendations impact the rapid testing arena? Which companies are the key players in this sector?

- With the increase in drug resistance among HIV/AIDS patients, resistance testing is playing a growing role in HIV disease management. Will the new CDC recommendations increase use of monitoring tests as well? What unmet needs remain in the resistance testing sector? Which companies are active in this area?

Scope

- Discussion of new CDC recommendations: revisions, rationale, target populations, and response to changes.

- Current HIV diagnostics: screening, confirmatory, and monitoring tests.

- Emerging HIV diagnostics: home test kits, replication capacity tests, and CCR5 and CXCR4 tests.

- Key players: profiles of select leaders in HIV diagnostics.

- Outlook for HIV diagnostics: impact of CDC guidelines on diagnostics and on drug treatment, constraints on routine testing, and strategic considerations.

Executive Summary Strategic Considerations Stakeholder Implications Introduction Revised Guidelines and Target Populations HIV Testing and Prevention Trends Background on HIV Guidelines and Impact of New Guidelines Factors Influencing the CDC Recommendations for Routine Screening Screening for HIV in the Health Care Setting Advantages of Rapid Screening Tests Monitoring of HIV-Infected Adults and Adolescents Baseline Measurement Timing of Treatment Initiation Timing of Therapy Switch Response of Various Professional Groups Regulation of HIV Diagnostics Impact of Routine HIV Testing on Patient Groups People Unaware of Their HIV Serostatus People Diagnosed at an Advanced Stage of Disease Pregnant Women Current Diagnostics Screening Tests Confirmatory Tests Monitoring Tests CD4 T-Cell Count Viral Load Test Resistance Tests Emerging Diagnostics Over-the-Counter HIV Home Test Kits Viral Fitness (Replication Capacity) Tests CCR5 and CXCR4 Tropism Tests Select Key Players in HIV Diagnostics OraSure Technologies BioMerieux Impact of CDC Guidelines on Routine HIV Screening Impact on Diagnostics Sectors Impact on Drug Treatment Constraints on Routine HIV Testing Strategic Considerations Development of Improved and New Products Influencing Decision Makers Synergy with Drugs Appendix A. Bibliography Appendix B. Explanation of Terms Used in This Report SPECTRUM Biomarkers and Diagnostics 2-3 CDC HIV Testing Guidelines Press Date: March 26, 2007 Decision Resources, Inc.

Tables Figures

Companies Mentioned: Abbott Laboratories Beckman Coulter Becton Dickinson BioMerieux Bio-Rad Laboratories Bristol-Myers Squibb Calypte Biomedical Celera Diagnostics Chembio Diagnostic Systems Gen-Probe Gilead Sciences GlaxoSmithKline Guava Technologies Home Access Health LabCorp MedMira Laboratories Monogram Biosciences Murex Diagnostics OraSure Technologies Partec Pfi zer Roche Molecular Diagnostics Siemens Medical Solutions Diagnostics Specialty Laboratories Trinity Biotech Virco ViroLogic Visible Genetics Waldheim Pharmazeutika

For more information visit http://www.researchandmarkets.com/reports/c55898

Source: Business Wire

More News in this Category